BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, Han KH, Kim DY; Korea Central Cancer Registry. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016;31:842-847. [PMID: 26513311 DOI: 10.1111/jgh.13218] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Kim DY, Han K. Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update? Hepatology 2018;67:2076-8. [DOI: 10.1002/hep.29748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Peng C, Li C, Liu C, Wen T, Yang J, Li B, Yan L. The outcome of the HCC patients underwent ALPPS: Retrospective study. Medicine (Baltimore) 2019;98:e17182. [PMID: 31567959 DOI: 10.1097/MD.0000000000017182] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
5 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
6 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
7 Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Kim JH, Yeon JE, Lee SW, Byun KS, Um SH. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. Liver Int. 2019;39:1109-1119. [PMID: 30972935 DOI: 10.1111/liv.14117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kudo M. Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer 2016;5:91-6. [PMID: 27386427 DOI: 10.1159/000367768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
9 Yi PS, Wang H, Li JS. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(3): 85-92 [PMID: 32218891 DOI: 10.4240/wjgs.v12.i3.85] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim YJ, Jung J, Joo JH, Kim SY, Kim JH, Lim YS, Lee HC, Kim JH, Yoon SM. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiother Oncol 2019;141:95-100. [PMID: 31506181 DOI: 10.1016/j.radonc.2019.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
11 Cho IR, Lee HW, Song KJ, Kim BK, Kim SU, Kim DY, Ahn SH, Seong J, Han KH, Park JY. Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget 2017;8:79914-26. [PMID: 29108373 DOI: 10.18632/oncotarget.20321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Huang C, Zhu XD, Ji Y, Ding GY, Shi GM, Shen YH, Zhou J, Fan J, Sun HC. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. BMC Cancer 2017;17:58. [PMID: 28095820 DOI: 10.1186/s12885-017-3050-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
13 Liu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D. Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics. Front Oncol 2020;10:539692. [PMID: 33072569 DOI: 10.3389/fonc.2020.539692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
15 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [DOI: 10.1002/hep.29668] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
16 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
17 Cho HJ, Kim SS, Kang SY, Yang MJ, Noh CK, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY; Korean Liver Cancer Association. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. Gut Liver 2019;13:557-68. [PMID: 31023007 DOI: 10.5009/gnl18444] [Cited by in F6Publishing: 3] [Reference Citation Analysis]